Abbott India signs patent license agreement with Takeda Pharmaceuticals

20 Sep 2024 Evaluate

Abbott India has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to market and distribute ‘Vonoprazan’ in India under the brand name ‘Vonefi’. Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. 

Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India. 

Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India. 


Abbott India Share Price

29939.60 465.80 (1.58%)
06-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1846.95
Dr. Reddys Lab 1350.65
Cipla 1490.55
Lupin 2357.75
Zydus Lifesciences 961.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.